Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.
SOURCE Galderma USA
FORT WORTH, Texas, Jan. 15, 2014 /PRNewswire/ -- Humberto C. Antunes, Galderma worldwide CEO, will receive a "Lifetime in Dermatology Achievement Award" from the Journal of Drugs in Dermatology (JDD) at the upcoming Orlando Dermatology Aesthetic & Clinical Conference (ODAC). The event is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate in Florida.
The ODAC is a distinguished event that delivers a comprehensive report on the practice of dermatology for clinical and aesthetic dermatology practitioners in the 21st century. It delivers the most progressive medical, surgical and cosmetic practices by the foremost leaders in dermatology today.
The Journal of Drugs in Dermatology (JDD), a peer-reviewed publication, was founded by Perry Robins, MD. Now in its 11th year, it offers one of the fastest routes for disseminating dermatologic information.
In 2013, the JDD requested nominations from the entire dermatology community, including the JDD editorial board, authors, and reviewers, for those companies regarded among their peers as the very best thought leaders in a particular dermatology specialty.
Galderma was elected to receive the prestigious JDD Leaders of Distinction Award and chosen as the Leader of Distinction for the "Lifetime in Dermatology Achievement Award."
"Galderma is one of the world's leading pharmaceutical companies in dermatology, and also one of the most generous, much of which would not be possible without Humberto Antunes' leadership, dedication and philanthropy to the industry," said Dr. Robins, ODAC Conference Chair Emeritus and Professor Emeritus of Dermatology at New York University School of Medicine.
"I have had the pleasure of knowing Humberto for many, many years and in that vein, it gives me great pleasure to honor him with the Journal of Drugs in Dermatology 'Lifetime in Dermatology Achievement Award,' and know that he will continue to positively shape the future of dermatology," added Dr. Robins.
"I will be truly honored to receive the 'Lifetime in Dermatology Achievement Award' in person at the ODAC meeting on January 17 and I accept it on behalf of 5,000 very deserving Galderma employees worldwide," said Antunes.
Following the receipt of the award, Antunes will also serve as the ODAC key note speaker, presenting his vision of the "Future of Dermatology" and addressing questions from 400 healthcare professionals.
Galderma's CEO is a Brazilian-born, Swiss-based dermatology veteran with 30 years of experience. He has been with Galderma for 17 years.
"At Galderma, our only focus is to improve the lives of people, all over the world, who suffer from skin conditions. Galderma is the only truly global company solely focused on dermatology and providing medical solutions for people with skin needs. The science of skin, hair and nails abounds with endless opportunities for new discoveries, and treatments in this area can improve the overall health and quality of people's lives immeasurably," said Antunes. "At Galderma, we are proud of our ongoing commitment to shape the future of the practice and science of dermatology."
About Galderma: A world leading medical company exclusively focused on dermatology
Since its inception in 1981 as a joint-venture between worldwide leaders Nestle and L'Oreal, Galderma has chosen to solely focus on dermatology. Galderma is committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. With approximately 20% of global revenues invested each year to discover and develop new products, Galderma is one of the world's leading investors in dermatology Research and Development. Strategic brands in the U.S. include Cetaphil®, Epiduo®, Oracea®, Mirvaso®, Clobex®, Differin®, MetroGel®, Vectical®, Tri-Luma® and Pliaglis®.For more information, please visit GaldermaUSA.
About Orlando Dermatology Aesthetic & Clinical Conference (ODAC)
A product of SanovaWorks, ODAC offers interactive workshops, live demonstrations, and presentations from top industry leaders. ODAC uses a state-of-the-art audience response system, unrivaled in similar industry meetings, that adds an element of excitement and interactivity, all while providing Continuing Medical Education (CME) credits to conference delegates. To watch live video coverage, visit OrlandoDerm.org. For more information about SanovaWorks other products and services, visit SanovaWorks.
About Journal of Drugs in Dermatology (JDD)
The Journal of Drugs in Dermatology (JDD) is a full-color, peer-reviewed publication indexed with MEDLINE®/PubMed®. Founded by the renowned Dr. Perry Robins, MD and now in it's 12th year, it offers one of the fastest routes to disseminate dermatologic information, and is considered the fastest growing publication in dermatology. JDD presents original articles, award-winning case reports, and timely features pertaining to new methods, techniques, and drug therapy in dermatology. Articles are reviewed by an International Editorial Board of over 150 renowned experts. JDD reaches around 14,500 dermatology healthcare professionals and has been recognized as the official publication of the International Society of Dermatologic Surgery (ISDS) and the Orlando Dermatology Aesthetic and Clinical (ODAC) Conference. Visit JDDonline.com for article archives, access to CME activities, supplements and author instructions. For more information, visit JDD.
©2012 PR Newswire. All Rights Reserved.